HomeNewsBusinessEconomyUS opposes massive liquidity IMF boost: Steven Mnuchin

US opposes massive liquidity IMF boost: Steven Mnuchin

The move was first floated by IMF Managing Director Kristalina Georgieva last month and is supported by many finance ministers, prominent economists and non-profit groups.

April 16, 2020 / 20:33 IST
Story continues below Advertisement

The United States opposes creation of liquidity through issuance of the International Monetary Fund's Special Drawing Rights (SDRs) as part of the response to the coronavirus pandemic, US Treasury Secretary Steven Mnuchin said on Thursday.

In a statement to the IMF's steering committee, Mnuchin said 70% of the funds created through an SDR allocation, something akin to a central bank "printing" new money, would go to G20 countries, most of whom did not need it, while only 3% would go to low-income countries.

Story continues below Advertisement

The 24-member International Monetary and Financial Committee is meeting on Thursday to review the IMF's response to the pandemic and a possible SDR allocation that could provide hundreds of billions of dollars in urgently needed foreign exchange reserves for all of the IMF's 189 members.

The move was first floated by IMF Managing Director Kristalina Georgieva last month and is supported by many finance ministers, prominent economists and non-profit groups. But Washington, the IMF's dominant shareholder, is blocking an allocation because it would give new avenues of funding for Iran and China, Reuters reported this week.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show